Innovation Pathway? Why Not Fix Expedited Review, AdvaMed Suggests
This article was originally published in The Gray Sheet
Executive Summary
FDA should improve its existing expedited review process for medical devices before investing its limited resources in a brand new innovation pathway, AdvaMed says.